Granules India's US Facility Completes FDA Audit with 4 Observations

Granules India's US subsidiary, Granules Pharmaceuticals, Inc., has completed a routine cGMP audit by the US FDA at its Chantilly facility.
The audit, conducted from March 30 to April 3, 2026, resulted in four observations on procedural matters, with no data integrity issues reported.
The company has committed to addressing the US FDA's observations within the stipulated timelines.